Q-omics provides the consensus-scored ATOH7 profile across patient tissues and cancer cell-line models. ATOH7 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, ATOH7 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, ATOH7 RNA expression shows 13,916 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight OV, KICH, and UVM as cancer lineages where ATOH7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATOH7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATOH7 survival associations across molecular data types. ATOH7 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATOH7 RNA expression–survival associations across cancer types. High ATOH7 expression shows unfavorable associations in ACC and SCLC, but favorable associations in OV, UCS, KIRP and MESO. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify OV as the clearest survival context for ATOH7 RNA expression.
This table summarizes ATOH7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ATOH7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATOH7 shows lower tumor expression in KICH, LIHC and BRCA and higher tumor expression in HNSC, UCEC and LUSC. The KICH box plot shows higher ATOH7 RNA expression in normal versus tumor tissue (log2 FC = −0.598, t-test p < 0.001).
This table shows molecular features associated with ATOH7 in patient tissues and cancer cell lines. In patient samples, ATOH7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ATOH7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and CNS.
